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Streptococcus pneumoniae is a leading cause
of pneumonia, meningitis, bacteremia, and
death in young children. A polysaccharide
vaccine has been recommended for use in
chronically ill children and adults 2 to 64 years of
age, as well as all adults >65 (1). While many
studies have assessed the immunogenicity of the
polysaccharide vaccine, scant data exist on its
effectiveness in younger children.
More than 90 serotypes of S. pneumoniae
have been described (2); however, most invasive
infections in the United States are caused by
<10 serotypes (3). Pneumococcal vaccines
available since 1978 consist of a mixture of
capsular polysaccharides from the most common
serotypes causing invasive disease. This vaccine
is recommended for children >2 years of age with
underlying diseases or immunosuppressive
medical treatments that are risk factors for
invasive pneumococcal disease (1,3).
Clinical trials of pneumococcal polysaccha-
ride vaccine effectiveness in children have
shown conflicting results (4-7). Vaccine failure in
immunized children has been reported (8), and
one study comparing immunization with
antibiotic prophylaxis in children with sickle cell
disease concluded that the vaccine was inferior
to penicillin prophylaxis (9). Uncertainty
regarding the effectiveness of vaccination may
contribute to low vaccination rates among
persons at risk for pneumococcal disease (1).
In indirect cohort analysis (10), the
distribution of pneumococcal serotypes causing
invasive disease among vaccinated and unvacci-
nated groups is compared. If the vaccine is
effective, vaccinated persons have fewer infec-
tions with serotypes represented in the vaccine
than unvaccinated persons. This method has
been used to calculate an overall effectiveness of
57% in persons >5 years of age, based on
serotypes of invasive isolates obtained through a
national, voluntary sentinel surveillance system
(11). Using data from national surveillance, we
examined vaccine effectiveness for children 2
through 5 years of age.
The Study
Since 1978, a national, hospital laboratory-
based surveillance system has collected data on
invasive pneumococcal disease (12). Participat-
ing institutions are requested to report all
pneumococcal isolates obtained from normally
sterile body sites, along with information on the
patient’s age, sex, symptoms, underlying
diseases, and vaccination history. The specifics
of how demographic and vaccination information
is collected are the responsibility of participating
institutions. Isolates are serotyped at the
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To estimate the effectiveness of pneumococcal polysaccharide vaccine, we
serotyped isolates submitted to the Pneumococcal Sentinel Surveillance System from
1984 to 1996 from 48 vaccinated and 125 unvaccinated children 2 to 5 years of age.
Effectiveness against invasive disease caused by serotypes included in the vaccine
was 63%. Effectiveness against serotypes in the polysaccharide vaccine but not in a
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Figure 1. Invasive pneumococcal infections among
173 children ages 2 through 5 years (24-59 months),
by serotype. Bottom bar represents proportion of total
invasive infections in the cohort caused by each
serotype. Top bar depicts cumulative proportion of
invasive infections caused by serotypes represented
by the bars to the left. Serotypes in the “other”
category included 19 serotypes with three or fewer
isolates. Two isolates could not be serotyped.
Figure 2. Frequency of various underlying chronic
illnesses among 173 children with invasive pneumococ-
cal disease. The category “malignancy” excluded
hematopoetic malignancies, which are included in the
leukemia category. Organ transplant includes both
solid organ and bone marrow transplants. CSF is
cerebrospinal fluid.
Centers for Disease Control and Prevention on
the basis of capsular swelling with serotype-
specific antisera (Quellung reaction).
Children included in the analysis were 24 to
59 months of age with one or more chronic
illnesses, had vaccination status and date
indicated on the surveillance form, received
vaccine between January 1984 and April 1996,
and had onset of invasive pneumococcal disease
between January 1984 and April 1996. Only
isolates from cerebrospinal fluid (CSF) or blood
were considered in the analysis. Information on
antibiotic prophylaxis was not collected. Chronic
illness was defined as an underlying illness
considered a risk factor for invasive pneumococ-
cal disease and an indication for vaccination (3).
Vaccine effectiveness was defined as the
percentage of reduction in the risk for infection
from serotypes included in the vaccine (vaccine-
type serotypes) among vaccinated persons
compared with unvaccinated persons. Infections
with vaccine-related serotypes (6A, 9A, 9L, 18B,
18F, 23A) not specifically included in the vaccine
were categorized as infections with nonvaccine
serotypes, except where noted. Effectiveness was
expressed as 1 minus the odds ratio x 100%; the
95% confidence intervals (also x 100%) were
calculated by the methods of Cornfield when cell
sizes were all greater than five subjects and by
exact methods otherwise. Calculations were
performed with Epi-Info version 6.02 (CDC/World
Health Organization, Atlanta, GA) with the
EXACT supplemental program (David O. Martin).
We performed a preliminary analysis of all
pneumococcal isolates from children in the
database to determine the proportion of vaccine-
type organisms in unvaccinated persons by sex,
underlying illness, or state of residence.
Proportions of vaccine-type serogroups did not
differ by underlying illness or by sex. Because
the proportion of vaccine-type isolates from
children from Alaska was 92.3%, compared with
the 85.4% of isolates from children from other
states (chi-square = 6.3; p <0.02), children from
Alaska were excluded from the analysis.
The analysis included 173 children, 52%
male, median age 3 years; 48 children (28%) had
received vaccine before acquiring invasive
pneumococcal disease. Isolates were obtained
from blood only from 156 children (90%), from
CSF only from 10 children (6%), and from both
sites from 7 children (4%). The median time
between date of vaccination and date of specimen
collection was 338.5 days (33 days to 1,341 days),
and no child had been vaccinated within 30 days
of invasive pneumococcal infection. Of serotypes
from the 173 invasive infections, serotypes 4, 6A,
6B, 14, 23F, 19F, 9V, and 18C accounted for 81%
of the isolates (Figure 1).
Forty-six (27%) of children in the study had
sickle cell disease (Figure 2). The “other”
category included children with congenital
anomalies such as congenital heart or lung
defects, children with anatomic asplenia, and
children on immunosuppressive medication
regimens. Thirty-three (69%) of 48 vaccinated
children had sickle cell disease.830 830 830 830 830 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
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Table. Estimates of pneumococcal polysaccharide vaccine effectiveness among 173 children 2 through 5 years of
age, using the indirect cohort method
Vaccine serotype/total(%)
Group Vaccinated childrena Unvaccinated childrena Effectiveness (95% CI)b
All children 35/48 (73) 110/125 (88) 63% (8% to 85%)
Children with SCD 27/33 (82)   12/13 (92) 62% (-294% to 98%)
Children without SCD   8/15 (53)   98/112 (88) 84% (40% to 96%)
Nonconjugate vaccine serotypec   1/14 (7)   18/33 (55) 93% (45% to 100%)
a23-valent pneumococcal polysaccharide vaccine.
bEffectiveness (95% confidence interval) estimated as (1- odds ratio or 95% confidence bound) x 100%.
cChildren infected with a serotype not in proposed conjugate vaccine (15) (excludes children infected with serotypes 4, 6B, 9V,
14, 18C, 19F, 23F).
SCD, sickle-cell disease.
The Table presents vaccine effectiveness
estimates for the overall cohort and for children
with and without sickle cell disease. For children
with the disease, the lower bound of the 95%
confidence interval included 0%. The estimate of
vaccine effectiveness for children without sickle
cell disease was higher than the estimate for
children with the disease. Point estimates of
effectiveness for children with nephrotic syn-
drome or HIV infection were 80%; however, the
95% confidence intervals included 0% (data not
shown). Other chronic diseases reported in this
cohort included leukemia, nonhematopoetic
malignancy, and organ transplant; however,
none of the children with these underlying
diseases were vaccinated, and effectiveness
could not be calculated.
Protein conjugate vaccines offer the advan-
tage of being effective in the first 2 years of life,
when response to polysaccharide vaccines is
poor. However, the number of serotypes that can
be represented in these vaccines is limited. To
evaluate polysaccharide effectiveness for sero-
types not represented in a protein conjugate
vaccine under evaluation for license (13), we
excluded children infected with serotypes 4, 6B,
9V, 14, 18C, 19F, and 23F. Polysaccharide vaccine
was highly effective in preventing invasive disease
due to serotypes included in the polysaccharide
vaccine but not in the conjugate vaccine (Table).
If the 14 children with serotypes 6A, 9A, 9L, 18B,
18F, and 23A are also excluded (because of
potential protection conferred by the proposed
conjugate vaccine for these vaccine-related
serotypes), the vaccine effectiveness estimate is
92% (exact 95% confidence intervals 17% to 100%).
Conclusions
Case-control studies have demonstrated that
pneumococcal capsular polysaccharide vaccines
are effective (14-16) and cost-effective (17,18) in
the prevention of invasive pneumococcal disease
among elderly and chronically ill adults. We used
data from a national sentinel surveillance
system for invasive pneumococcal disease to
determine whether children ages 2 to 5 years
were also protected. An overall vaccine
effectiveness of 63% was demonstrated by
indirect cohort analysis (15). The indirect cohort
analysis presented here strengthens the case for
the use of pneumococcal polysaccharide vaccine
for children with underlying conditions.  For
children with sickle cell disease, penicillin
prophylaxis remains the most effective preven-
tive measure for reducing pneumococcal disease.
Accuracy of vaccine history is critical to this
analysis and may vary between surveillance
sites. To minimize inaccuracies, patients with no
indication of vaccine history were excluded. For
those with a reported vaccine history,
misclassification due to inaccurate history
should be as likely among patients with vaccine-
type as among nonvaccine-type infections
because the serotype of patient isolates was not
known when vaccine status was determined
(serotyping was done at CDC). Bias due to this
nondifferential misclassification will be towards
the null hypothesis (no effect of vaccination) (19).
Newly developed pneumococcal protein
conjugate vaccines are safe and immunogenic for
infants and young children (13,20,21). Prelimi-
nary results from a large, Phase-III trial of a
heptavalent conjugate vaccine among healthy
children indicate substantial efficacy in prevent-
ing invasive disease (13). However, the expense
and technical difficulty of creating conjugates for
each serotype will likely limit the number of
serotypes represented in a polyvalent conjugate
vaccine to fewer than 12. Available data suggest
that polysaccharide vaccine, when administered
after primary immunization with a conjugate
vaccine, elicits a significant booster effect in831 831 831 831 831 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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healthy infants (22) equivalent to the booster
response engendered by a second conjugate
vaccine series (23). These results and the level of
effectiveness seen with pneumococcal polysac-
charide vaccine in our study suggest that the
polysaccharide vaccine will still be a useful adjunct
to conjugate vaccine, by providing additional
protection to children >2 years of age for whom
polysaccharide vaccine is currently indicated.
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